Headaches: Nonsurgical Management — CPB 0462 | AETNA Coverage Update

Aetna modified CPB 0462 for nonsurgical headache management, effective March 3, 2026. Here's what changes for billing teams.

Aetna, a CVS Health company, updated Clinical Policy Bulletin 0462 to clarify medical necessity criteria and expand the list of experimental or unproven interventions. This coverage policy directly affects emergency medicine, neurology, and infusion billing teams who submit claims using HCPCS codes like J1110 (dihydroergotamine), J1885 (ketorolac tromethamine), and J3032 (eptinezumab-jjmr). The non-covered list now includes dozens of drug and device codes — from J2704 (propofol) to A4540 (Cefaly headband) — that are easy to bill and hard to recoup after a claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Headaches: Nonsurgical Management
Policy Code	CPB 0462
Change Type	Modified
Effective Date	March 3, 2026
Impact Level	High
Specialties Affected	Emergency Medicine, Neurology, Infusion/Infusion Centers, Pain Management, Headache Clinics
Key Action	Audit charge capture for all injectable migraine treatments against CPB 0462's covered and non-covered HCPCS lists before billing any Aetna claim

---

Aetna Headache Management Coverage Criteria and Medical Necessity Requirements 2026

The real complexity in this Aetna headache management coverage policy is the IV dihydroergotamine (DHE) criteria. Aetna covers IV DHE — billed as HCPCS J1110 — but only in four tightly defined situations.

Status migrainosus (ICD-10 G43.011, G43.101) qualifies when the migraine has lasted more than 72 hours and the member is in an emergency room, urgent care, or hospital setting. Outside that setting, this coverage disappears. That's a documentation requirement your team needs to capture in real time, not reconstructed after the fact.

Intractable severe migraine that has failed analgesics and triptans also qualifies — but only in the ER, hospital, or urgent care setting. Aetna spells out the triptan list explicitly: Almotriptan, Amerge, Axert, Frova, Imitrex, Imitrex nasal spray, Maxalt, Maxalt MLT, Onzetra Xsail, Relpax, Sumavel, Treximet, zolmitriptan, zolmitriptan ODT, Zomig, and Zomig ZMT. If the medical record doesn't show that the member tried and failed triptans, expect a denial.

Cluster headache that fails oxygen and triptans in an acute care setting is a covered indication. Medication overuse headache is covered only in the inpatient setting — not urgent care, not outpatient infusion.

Beyond DHE, Aetna considers these treatments medically necessary when criteria are met:

---

Aetna Headache Management Exclusions and Non-Covered Indications

This is where the policy gets expensive if your team isn't current on the billing guidelines.

Aetna classifies a long list of interventions as experimental, investigational, or unproven. The practical meaning: claims for these services against Aetna migraine diagnosis codes will deny. Build these into your billing scrubber now.

IV DHE exclusions are narrow but important. Aetna will not cover J1110 for any headache type outside the four covered indications. Specifically, members with intermittent migraine who are not actively in a prolonged, debilitating attack at the time of admission do not qualify. This is a common billing gap — the provider treats the patient, the coder pulls a migraine ICD-10, and no one checks whether the admission criteria were met.

Injectable and infusion therapies flagged as non-covered include:

A note on IV magnesium sulfate (J3475): The policy lists J3475 in the covered HCPCS codes section. However, IV magnesium as a migraine intervention also appears in the experimental interventions section — without a specific J code assignment. These two positions appear to conflict. Do not treat J3475 as a straightforward covered or excluded code without confirming with Aetna directly how they apply J3475 for migraine indications. This is worth a payer call before you bill it.

Antipsychotics and antiemetics used as migraine abortives are also non-covered: haloperidol (J1630, J1631), droperidol (J1790), promethazine (J2550, Q0169), promazine (J2950), diphenhydramine (J1200, Q0163), and benztropine (J0515). These are commonly given in the ER as migraine adjuncts. Billing them under migraine ICD-10 codes against Aetna will generate denials.

Device and neuromodulation therapies flagged as experimental:

Nerve blocks and injections not covered for headache indications:

Oral and preventive therapies flagged as experimental:

Cranio-sacral therapy and intra-oral splints (CPT 21085, dental codes D4322 and D4323) are explicitly non-covered.

The real issue here is the anti-emetic and adjunct drug list. Emergency departments routinely give these agents during migraine treatment and bill them under the same encounter. Your ER billing team needs to understand that reimbursement for J1630, J1790, J2550, and related codes is off the table for migraine encounters with Aetna.

---

Coverage Indications at a Glance

---

Aetna Headache Billing Guidelines and Action Items 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Headache Management Under CPB 0462

Covered HCPCS Codes (When Selection Criteria Are Met)

Covered CPT Codes (Other Related Codes)

Not Covered / Experimental CPT Codes

Not Covered / Experimental HCPCS Codes

Key ICD-10-CM Diagnosis Codes

---